Firm is currently upgrading a former Dell Computer site into the largest capacity bulk biologics production facility in the region
US biopharmaceuticals firm Regeneron Pharmaceuticals is investing an additional US$350m at its Limerick, Ireland plant and will add a further 200 jobs.
The investment in its Limerick industrial operations and product supply (IOPS) bioprocessing campus will bring the total number of jobs at Regeneron in Ireland to 500 by the end of 2017.
The company acquired the former Dell Computer facility in Limerick and is currently transforming the site into a purpose-built facility that will house the largest capacity bulk biologics production facility in Ireland.
Recruitment is currently underway to bring on additional full-time, high-end specialist jobs in commercial manufacturing, process sciences, quality assurance/control and various support functions for scientists, chemists and technicians.
According to Regeneron 1,200 contractors were onsite to support development.
Regeneron's President and Chief Executive Leonard Schleifer said: 'With a growing portfolio of marketed medicines and an innovative pipeline rooted in cutting-edge science and technology, Regeneron is one of the fastest-growing global biopharmaceutical companies. The Limerick facility will play an essential role in ensuring Regeneron delivers on our mission to consistently and repeatedly bring new medicines to patients with serious diseases.'
Regeneron's 400,000ft2, state-of-the-art biologics production facility in Limerick is now operational with the first production line on track to enter validation before the end of this year.
The company has worked closely with the Department of Jobs and IDA Ireland on the development of its operations in the country.
In addition to IOPS operations in Limerick, Regeneron also has a growing multi-functional team in Dublin supporting its business in Europe.